CTNM Stock Analysis: Contineum Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 565m USD | 12M Return: 282.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.99M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Contineum Therapeutics, Inc. (CTNM) is a clinical-stage biopharmaceutical firm focused on developing small molecule therapies for neuroscience, inflammation, and immunology. Its primary pipeline includes PIPE-791, a brain-penetrant LPA1R inhibitor targeting idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, aimed at depression and multiple sclerosis. Formerly known as Pipeline Therapeutics, the company operates out of San Diego, California.
The clinical-stage biotech sector typically operates on a high-risk, high-reward model where valuation is driven by trial data milestones rather than immediate revenue. Small molecule development is often prioritized in neuroscience due to the ability of these compounds to cross the blood-brain barrier more effectively than larger biologics. Investors can further evaluate these technical pipeline milestones by utilizing the data tools at ValueRay.
- PIPE-791 clinical trial milestones drive valuation in pulmonary fibrosis and chronic pain
- Partnership revenue from Johnson & Johnson collaboration fuels PIPE-307 development for MS
- Regulatory approval pathways for brain-penetrant small molecules impact long-term commercial viability
- High research and development expenditures necessitate future capital raises or dilutive financing
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -2.11 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -57.2m > Net Income -58.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 38.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.3m) vs 12m ago 44.34% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.12%; Δ -0.12% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 253.0m - Total Current Liabilities 6.66m) / Total Assets 261.3m |
| B: -0.73 (Retained Earnings -191.8m / Total Assets 261.3m) |
| C: -0.25 (EBIT TTM -58.4m / Avg Total Assets 229.8m) |
| D: 22.11 (Book Value of Equity 250.0m / Total Liabilities 11.3m) |
| Altman-Z'' = 25.30 = AAA |
As of July 08, 2026, the stock is trading at USD 14.56 with a total of 491,420 shares traded. Over the past week, the price has changed by -2.93%, over one month by +26.28%, over three months by +14.38% and over the past year by +282.15%.
Current recommended Stop Loss: 13.10 (which is 10% or 1.3 ATR below the current price).
Contineum Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CTNM.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.3 | 53.4% |
P/S = 11.147
P/B = 2.272
Revenue TTM = 0.0 USD
EBIT TTM = -58.4m USD
EBITDA TTM = -58.1m USD
Long Term Debt = 4.65m USD (estimated: total debt 6.95m - short term 2.30m)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 6.95m USD (from shortLongTermDebtTotal, last quarter) (leases 6.95m already included)
Net Debt = -239.4m USD (calculated: Debt 6.95m - CCE 246.3m)
Enterprise Value = 325.2m USD (564.5m + Debt 6.95m - CCE 246.3m)
Interest Coverage Ratio = unknown (Ebit TTM -58.4m / Interest Expense TTM 0.0)
EV/FCF = -5.64x (Enterprise Value 325.2m / FCF TTM -57.7m)
FCF Yield = -17.73% (FCF TTM -57.7m / Enterprise Value 325.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 328k) / Revenue TTM)
Tobins Q-Ratio = 1.24 (Enterprise Value 325.2m / Total Assets 261.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.95m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.2m (EBIT -58.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 38.00 (Total Current Assets 253.0m / Total Current Liabilities 6.66m)
Debt / Equity = 0.03 (Debt 6.95m / totalStockholderEquity, last quarter 250.0m)
Debt / EBITDA = 4.12 (negative EBITDA) (Net Debt -239.4m / EBITDA -58.1m)
Debt / FCF = 4.15 (negative FCF - burning cash) (Net Debt -239.4m / FCF TTM -57.7m)
Total Stockholder Equity = 215.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.43% (Net Income -58.4m / Total Assets 261.3m)
RoE = -27.09% (Net Income TTM -58.4m / Total Stockholder Equity 215.7m)
RoCE = -26.52% (EBIT -58.4m / Capital Employed (Equity 215.7m + L.T.Debt 4.65m))
RoIC = -17.97% (negative operating profit) (NOPAT -46.2m / Invested Capital 257.0m)
WACC = 10.64% (E(564.5m)/V(571.5m) * Re(10.77%) + D(6.95m)/V(571.5m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 19.24%
[DCF] Fair Price = unknown (Cash Flow -57.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.18 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.45 | Chg30d=+19.48% | Revisions=+70% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.43 | Chg30d=+17.58% | Revisions=+70% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.65 | Chg30d=+19.88% | Revisions=+70% | GrowthEPS=+24.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.81 | Chg30d=+16.58% | Revisions=+44% | GrowthEPS=-10.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +83% (up=26, down=1)